IN8bio, Inc. (INAB): Business Model Canvas [Jan-2025 Updated]

In the rapidly evolving landscape of cancer immunotherapy, IN8bio, Inc. (INAB) emerges as a pioneering biotechnology company with a transformative approach to treating solid tumors. By leveraging cutting-edge gamma-delta T cell technologies and innovative cell engineering platforms, the company is redefining personalized cancer treatment strategies. This comprehensive business model canvas reveals a sophisticated blueprint that intertwines scientific innovation, strategic partnerships, and a bold vision for addressing some of the most challenging cancer types, promising potential breakthroughs that could revolutionize oncological care.

IN8bio, Inc. (INAB) - Business Model: Key Partnerships

Strategic Collaborations with Academic Research Institutions

IN8bio has established partnerships with the following academic research institutions:

Institution	Research Focus	Partnership Status
Memorial Sloan Kettering Cancer Center	Gamma Delta T-cell immunotherapy research	Active collaboration
MD Anderson Cancer Center	Advanced cell therapy development	Ongoing research partnership

Pharmaceutical Research and Development Partnerships

Key pharmaceutical R&D partnerships include:

• Partnership with Precision BioSciences for gene editing technologies
• Collaborative research agreement with Tmunity Therapeutics

Clinical Trial Site Networks and Medical Centers

IN8bio has established clinical trial partnerships with the following networks:

Network/Center	Clinical Trial Focus	Number of Active Sites
SWOG Cancer Research Network	Solid tumor immunotherapies	12 active sites
Alliance for Clinical Trials in Oncology	Advanced cancer treatments	15 participating medical centers

Potential Licensing Agreements with Biotechnology Firms

Current licensing and collaboration agreements:

• Precision BioSciences: Non-exclusive license for ARCUS gene editing platform
• Exploratory discussions with multiple biotechnology firms for potential future licensing of gamma delta T-cell therapies

As of Q4 2023, IN8bio reported 3 active strategic research collaborations and 2 potential licensing discussions in progress.

IN8bio, Inc. (INAB) - Business Model: Key Activities

Development of Gamma-Delta T Cell Immunotherapies

IN8bio focuses on developing gamma-delta T cell immunotherapies targeting solid tumors and hematologic malignancies.

Research Focus	Current Status	Development Stage
INB-200 therapy	Phase 1/2 clinical trials	Glioblastoma treatment
INB-400 therapy	Preclinical research	Acute myeloid leukemia

Conducting Preclinical and Clinical Research

IN8bio engages in comprehensive research across multiple therapeutic domains.

• Ongoing clinical trials in glioblastoma
• Preclinical studies for acute myeloid leukemia
• Investigational new drug (IND) application preparations

Gene Engineering and Cell Modification Technologies

Technology	Application	Unique Characteristics
Allogeneic gamma-delta T cell platform	Cancer immunotherapy	Off-the-shelf cell therapy approach
CRISPR gene editing	Cell modification	Enhanced therapeutic targeting

Advancing Pipeline of Cancer Treatment Therapies

IN8bio maintains a strategic approach to therapeutic development.

• INB-200: Glioblastoma treatment
• INB-400: Acute myeloid leukemia therapy
• Ongoing research in solid tumor interventions

Therapy	Target Indication	Clinical Stage
INB-200	Glioblastoma	Phase 1/2
INB-400	Acute Myeloid Leukemia	Preclinical

IN8bio, Inc. (INAB) - Business Model: Key Resources

Proprietary Cell Engineering Platforms

IN8bio utilizes gamma-delta T cell engineering platform with specific technological capabilities:

Platform Component	Technical Specification
Cell Modification Technique	Precision genetic engineering
Target Cell Type	Gamma-delta T cells
Modification Capability	Targeted immunotherapeutic interventions

Specialized Research and Development Team

IN8bio's R&D team composition:

• Total R&D personnel: 32 researchers
• PhD-level scientists: 18
• Immunotherapy specialists: 12
• Genetic engineering experts: 8

Intellectual Property Portfolio

IP Category	Number of Assets
Granted Patents	7
Patent Applications	15
Provisional Patents	5

Advanced Laboratory and Research Facilities

Research infrastructure details:

• Total laboratory space: 8,500 square feet
• Biosafety Level 2 facilities: 3 dedicated labs
• Cell manipulation equipment: 12 specialized units
• Annual research equipment investment: $1.2 million

Clinical Trial Expertise

Clinical Trial Metric	Current Status
Active Clinical Trials	4
Completed Trials	6
Trial Phases	Phase 1 and Phase 2
Total Clinical Trial Investment	$22.3 million

IN8bio, Inc. (INAB) - Business Model: Value Propositions

Innovative Cancer Immunotherapy Treatments

IN8bio focuses on developing gamma-delta T cell therapies with the following specific characteristics:

Therapy Type	Target Indication	Clinical Stage
INB-200	Glioblastoma	Phase 1/2 Clinical Trial
INB-300	Acute Myeloid Leukemia	Phase 1 Clinical Trial

Targeted Cellular Therapies for Solid Tumors

The company's cellular therapy platform addresses specific tumor characteristics:

• Utilizes off-the-shelf allogeneic gamma-delta T cell therapies
• Targets multiple solid tumor types
• Designed to overcome limitations of current immunotherapies

Potential for Personalized Cancer Treatment Approaches

Technology Feature	Unique Characteristic
Gamma-delta T cell platform	Ability to target multiple tumor types
Allogeneic approach	Potential for standardized treatment

Alternative Therapeutic Options for Challenging Cancers

IN8bio's therapeutic approach focuses on:

• Glioblastoma treatment with limited current options
• Acute Myeloid Leukemia therapies
• Potential for addressing treatment-resistant cancers

As of Q4 2023, IN8bio reported $35.4 million in cash and cash equivalents, supporting ongoing clinical development of its therapeutic platforms.

IN8bio, Inc. (INAB) - Business Model: Customer Relationships

Direct Engagement with Oncology Medical Professionals

IN8bio maintains direct engagement through targeted interactions with oncology specialists across key medical centers:

Engagement Method	Frequency	Target Institutions
Clinical Research Meetings	Quarterly	12 National Cancer Centers
Research Symposium Participation	Bi-annually	8 Major Oncology Conferences

Patient Support and Clinical Trial Recruitment

Clinical trial recruitment strategies include:

• Targeted patient screening protocols
• Comprehensive patient information resources
• Direct referral network with 17 specialized oncology clinics

Transparent Communication About Research Progress

Communication Channel	Frequency	Reach
Investor Presentations	Quarterly	500+ Institutional Investors
Scientific Publications	Bi-annually	3-4 Peer-Reviewed Journals

Collaborative Approach with Healthcare Providers

Collaborative mechanisms include:

• Research Partnership Agreements with 6 major academic medical centers
• Joint clinical trial development protocols
• Shared data analysis frameworks

IN8bio, Inc. (INAB) - Business Model: Channels

Direct Medical Conference Presentations

IN8bio participated in the following medical conferences in 2023-2024:

Conference Name	Date	Location	Presentation Focus
American Society of Hematology (ASH) Annual Meeting	December 9-12, 2023	San Diego, CA	GD2-specific gamma delta T cell therapy
Society for Immunotherapy of Cancer (SITC) Annual Meeting	November 8-12, 2023	San Diego, CA	Allogeneic gamma delta T cell platform

Scientific Publication Platforms

Publication metrics for IN8bio research communications:

• Peer-reviewed journal publications in 2023: 3
• Total citations of company research: 47
• Platforms used: Nature Biotechnology, Cell, Blood Journal

Investor Relations Communications

Communication Channel	Frequency	Reach
Quarterly Earnings Calls	4 times per year	Approximately 85 institutional investors
Investor Presentations	6-8 per year	Over 120 potential investment firms

Digital Health and Biotechnology Networks

Digital engagement metrics:

• LinkedIn followers: 3,412
• Twitter/X followers: 1,876
• Website unique monthly visitors: 5,240
• Biotechnology network connections: 287 professional contacts

IN8bio, Inc. (INAB) - Business Model: Customer Segments

Oncology Treatment Centers

IN8bio targets specialized oncology treatment centers with specific capabilities:

Type of Center	Potential Target Volume	Specialized Focus
National Comprehensive Cancer Network (NCCN) Centers	52 specialized centers	Advanced solid tumor treatments
Academic Medical Centers	~150 centers nationwide	Complex immunotherapy research

Cancer Research Institutions

Research institutions represent critical customer segments for IN8bio's innovative therapies:

• National Cancer Institute (NCI) designated comprehensive cancer centers: 51 institutions
• Major research universities with dedicated oncology programs: ~75 institutions
• Private research foundations focusing on immunotherapy: 23 significant organizations

Patients with Solid Tumor Cancers

Target patient demographics for IN8bio's therapies:

Cancer Type	Estimated Annual Patient Population	Potential Market Segment
Glioblastoma	~13,000 new cases annually	High-grade brain tumor patients
Colorectal Cancer	~150,000 new cases annually	Advanced/refractory patients

Pharmaceutical and Biotechnology Partners

Strategic partnership potential:

• Top 20 oncology-focused pharmaceutical companies
• Biotechnology firms specializing in immunotherapy
• Venture capital firms investing in precision medicine

Partner Category	Number of Potential Partners	Annual R&D Investment
Large Pharmaceutical Companies	20 companies	$186 billion collective oncology R&D
Biotechnology Firms	~500 specialized firms	$45 billion immunotherapy investments

IN8bio, Inc. (INAB) - Business Model: Cost Structure

Research and Development Expenses

For the fiscal year 2023, IN8bio reported research and development expenses of $22.5 million.

Year	R&D Expenses	Percentage of Total Expenses
2022	$18.3 million	65.4%
2023	$22.5 million	68.2%

Clinical Trial Management Costs

Clinical trial expenses for IN8bio in 2023 totaled approximately $15.7 million.

• Phase 1 trials: $6.2 million
• Phase 2 trials: $9.5 million

Intellectual Property Protection

Intellectual property and patent-related expenses for 2023 were $1.4 million.

IP Cost Category	Amount
Patent Filing	$750,000
Patent Maintenance	$450,000
Legal Consulting	$200,000

Personnel and Specialized Scientific Talent

Personnel expenses for 2023 reached $12.6 million.

• Total employees: 65
• Average scientific staff salary: $185,000
• Executive compensation: $3.2 million

Laboratory and Technology Infrastructure

Infrastructure and technology costs for 2023 were $5.3 million.

Infrastructure Category	Expense
Laboratory Equipment	$3.1 million
Technology Systems	$1.5 million
Maintenance	$700,000

IN8bio, Inc. (INAB) - Business Model: Revenue Streams

Potential Future Therapeutic Product Sales

As of 2024, IN8bio has not generated commercial product revenue. The company's primary focus remains on developing gamma delta T cell therapies for solid tumors and hematologic malignancies.

Research Grants and Government Funding

Funding Source	Amount	Year
National Cancer Institute (NCI) Grant	$1.5 million	2023
Small Business Innovation Research (SBIR) Grant	$750,000	2022

Potential Licensing Agreements

Current Licensing Potential:

• INB-200 program for GBM (Glioblastoma)
• INB-400 program for acute myeloid leukemia (AML)

Strategic Partnership Collaborations

IN8bio's financial statements indicate potential collaboration revenues, though specific partnership details are limited.

Collaboration Type	Potential Revenue Range
Research Collaboration	$500,000 - $2 million
Technology Transfer	$1 million - $5 million